ORIC News and Press, Oric Pharmaceuticals Inc. From 11/06/25

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the publication of a peer-reviewed research...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented posters at the 2025 EORTC-NCI-AACR International ...

2025-10-17 07:01:47 ET Shares of autoimmune and oncology concern Cullinan Therapeutics, Inc. ( CGEM ) are down approximately 70% since May 2024, owing to a data vacuum from its off-the-shelf CD19xCD3 T cell engager CLN-978. The now autoimmune therapy should provide eagerly await...

2025-09-03 19:37:13 ET ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT... Read the full article on Seeking Alpha For further details see: ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. ...

2025-08-12 16:53:04 ET More on ORIC Pharmaceuticals ORIC Pharmaceuticals: What It Takes To Be Best In Class ORIC Pharmaceuticals announces $125M private placement to advance cancer pipeline Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals Historica...

Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top-tier healthcare specialist investors...

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...

Oric Pharmaceuticals Inc. (ORIC) is expected to report $-0.46 for Q2 2025

2025-08-06 07:58:52 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: ORIC Pharmaceuticals: What It Takes To Be Best In Class

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The rising burden of cancer is poised to strain both healthcare systems and patient finances, especially as cases continue to climb. At the same time, signals out of Wa...